For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,741 | 11,980* | 4,534 | 4,643 |
| Research and development | 61 | 242* | 6,127 | 6,232 |
| (loss) gain on fair value remeasurement of contingent consideration | - | -2,361* | 4,833 | -153 |
| Impairment of right-of-use assets | - | -2,822* | 1,411 | - |
| Total costs and expenses | 1,802 | 11,760 | 7,239 | 11,028 |
| Loss from operations | -1,802 | -11,760* | -7,239 | -11,028 |
| Interest income | 74 | 125* | 270 | 407 |
| Interest expense | - | 210* | 963 | 1,081 |
| Grant income | - | 1,837* | 480 | 547 |
| Gain on extinguishment of debt | - | 1,448* | - | - |
| Other income (expense), net | 107 | 9,661* | -112 | - |
| Total other income (expense) | 181 | 12,860* | -325 | -127 |
| Net gain | - | 1,099 | -7,564 | -11,155 |
| Net loss and comprehensive loss | -1,621 | - | - | - |
| Basic EPS | -0.14 | 0.101 | -1.07 | -1.71 |
| Diluted EPS | -0.14 | 0.101 | -1.07 | -1.71 |
| Basic Average Shares | 11,873,568 | 10,889,260 | 7,042,457 | 6,513,108 |
| Diluted Average Shares | 11,873,568 | 10,889,260 | 7,042,457 | 6,513,108 |
KALA BIO, Inc. (KALA)
KALA BIO, Inc. (KALA)